Close Menu

NEW YORK (GenomeWeb) – Labcyte and Notable Labs said today that they have inked an agreement under which Notable Labs will use Labcyte's Echo acoustic liquid handling technology for personalizing drug therapy.

Notable, a clinical oncology company, will employ the Echo technology in its fully automated, high-throughput laboratory to functionally assess the effects of FDA-approved drugs on live primary cancer cells from individual patients, the companies said.

Financial terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Nature News reports that researchers in Japan hope to soon test the use of reprogrammed stem cells to treat damaged corneas.

A new approach may help limit the number of fish that are mislabeled at markets or restaurants, according to New Scientist.

At Slate, the R Street Institute's Nila Bala discusses the privacy rights of suspects that genetic genealogy approaches in law enforcement bring up.

In PNAS this week: numerous mobile genetic elements contribute to Vibrio cholerae drug resistance, troponin I mutations in sudden infant deaths, and more.